Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451974 | 0.85 | MEN1 (0.32) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452096 | 0.83 | MEN1 (0.44) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452100 | 0.82 | MEN1 (0.41) | MEN1PABPC1KMT2A | |
| SCHEMBL31452039 | 0.81 | KDM5A (0.31) | — | |
| SCHEMBL31451983 | 0.81 | KMT2A (0.45) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452056 | 0.81 | MEN1 (0.56) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452072 | 0.81 | MEN1 (0.41) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452105 | 0.81 | MEN1 (0.44) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31452009 | 0.80 | MEN1 (0.42) | BRD4MEN1PABPC1KMT2A | |
| SCHEMBL31451975 | 0.80 | PTGER4 (0.35) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025034537-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | PKD1, APC, VHL | BRD4 693/4885MEN1 1199/4885PABPC1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.